AQXP Aquinox Pharmaceuticals, Inc.

13.70
-0.34  -2%
Previous Close 14.04
Open 14.03
Price To book 2.40
Market Cap 320.90M
Shares 23,423,000
Volume 41,787
Short Ratio 20.38
Av. Daily Volume 96,953

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 failed to demonstrate efficacy November 2015
AQX-1125 KINSHIP
Atopic dermatitis (AD)
Phase 2 trail failed - July 2015
AQX-1125 FLAGSHIP
Chronic obstructive pulmonary disease (COPD)
Phase 2 trial did not meet endpoints - June 2015 but positive secondary endpoint data - August 2015. Phase 3 trial commenced September 2016. Reported March 9, 2017 that enrollment has been slower than expected. Data now due 2018.
AQX-1125 LEADERSHIP
Bladder pain syndrome/interstitial cystitis (BPS/IC).